Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

Efficacy of ustekinumab in concomitant asthma and atopic dermatitis

The efficacy and safety of adjuvant ustekinumab in patients with asthma and atopic dermatitis (AD) was evaluated in a German prospective, monocenter registry analysis from 2006-2008. Thirteen patients with allergic asthma and nine patients with concomitant allergic asthma and AD were included in the analysis. Ustekinumab doses ranged from 150-450 mg s.c./2 weeks. The Asthma Quality of Life Questionnaire (AQLQ) and Dermatology Life Quality Index (DLQI) and asthma-related treatments were assessed at baseline and 6 months after treatment. Co-therapy with ustekinumab and standard asthma treatments significantly improved the AQLQ and DLQI assessments and decreased the use of oral corticosteroids (Velling, P. et al. 28th Congr Eur Acad Allergol Clin Immunol (EAACI) (June 6-10, Warsaw) ...